EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Legend Biotech's enterprise value is $7,280.5 Mil.
Legend Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-487.8 Mil. Therefore, Legend Biotech's EV-to-EBITDA for today is -14.93.
The historical rank and industry rank for Legend Biotech's EV-to-EBITDA or its related term are showing as below:
LEGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.53 Med: -16.7 Max: -8.41
Current: -14.93
During the past 6 years, the highest EV-to-EBITDA of Legend Biotech was -8.41. The lowest was -30.53. And the median was -16.70.
LEGN's EV-to-EBITDA is ranked worse than 100% of 462
companies
in the Biotechnology industry
Industry Median: 9.55
vs LEGN: -14.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Legend Biotech EV-to-EBITDA Historical Data
The historical data trend for Legend Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Legend Biotech's EV-to-EBITDA
For the Biotechnology subindustry, Legend Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Legend Biotech's EV-to-EBITDA falls into.
Legend Biotech EV-to-EBITDA Calculation
Legend Biotech's EV-to-EBITDA for today is calculated as:
Legend Biotech's current Enterprise Value is $7,280.5 Mil.
Legend Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-487.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Legend Biotech's PE Ratio for today is calculated as:
Legend Biotech's share price for today is $45.41.
Legend Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.940.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Legend Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Legend Biotech (Legend Biotech) Business Description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LEGN has been successfully added to your 